Table 1.
Description of GWAS on HIV infection and the most interesting signals discovered
| cohort | year | Phenotype | Most important association | P-value | Validation | ethnicity | ref |
|---|---|---|---|---|---|---|---|
| CHAVI |
2007 |
RNA VL setpoint |
HCP5 (rs2395029) |
9.4E-12 |
Significant, confirmed |
Caucasian |
[27] |
| |
|
|
−35 HLA-C (rs9264942) |
3.8E-09 |
Significant, confirmed |
|
|
| |
|
CD4 T cell decline |
ZNRD1 (rs9261174) |
3.9E-07 |
Confirmed |
|
|
| ANRS PRIMO |
2008 |
plasma HIV RNA primary infection |
HCP5 (rs2395029) |
9.3E-07 |
Significant, confirmed |
Caucasian |
[31] |
| |
|
cellular HIV DNA primary infection |
HCP5 (rs2395029) |
6.7E-07 |
Significant, confirmed |
|
|
| GRIV |
2009 |
long-term nonprogression |
HCP5 (rs2395029) |
6.8E-10 |
Significant, confirmed |
Caucasian |
[32] |
| |
|
|
C6orf48 (rs9368699) |
5.3E-07 |
Putative |
|
|
| Euro-CHAVI, MACS |
2009 |
RNA VL setpoint |
HCP5 (rs2395029) |
4.5E-35 |
Significant, confirmed |
Caucasian |
[33] |
| |
|
|
−35 HLA-C (rs9264942) |
5.9E-32 |
Significant, confirmed |
|
|
| GRIV |
2009 |
rapid progression |
PRMT6 (rs4118325) |
6.1E-07 |
Putative |
Caucasian |
[34] |
| |
|
|
SOX5 (rs1522232) |
1.8E-06 |
Putative |
|
|
| International HIV controllers study |
2010 |
VL controllers |
>300 SNPs in MHC |
<5.0E-08 |
Significant |
Caucasian, African, Hispanic |
[35] |
| |
|
−35 HLA-C (rs9264942) |
2.8E-35 |
Significant, confirmed |
|
||
| |
|
HCP5 (rs2395029) |
9.7E-26 |
Significant, confirmed |
|
||
| |
|
MICA (rs4418214) |
1.4E-34 |
Significant |
|
||
| |
|
PSORSIC3 (rs3131018) |
4.2E-16 |
Significant |
|
||
| Queen Elizabeth Central Hospital, Malawi |
2010 |
mother-to-child transmission |
HS3ST3A1 (rs8069770) |
3.8E-05 |
Putative |
African |
[36] |
| MACS |
2010 |
progression to AIDS |
PROX1 (rs17762192) |
6.2E-07 |
Confirmed |
Caucasian |
[37] |
| DoD HIV NHS and MACS |
2010 |
RNA VL setpoint |
HLA-B*5703 |
5.6E-10 |
Significant, confirmed |
African |
[38] |
| GRIV, MACS, ACS |
2010 |
long-term nonprogression (VL > 100 cp/ml) |
CXCR6 (rs2234358) |
9.7E-10 |
Significant, confirmed |
Caucasian |
[39] |
| CHAVI, Malawi |
2011 |
HIV acquisition |
|
|
|
African |
[40] |
| MACS |
2011 |
progression to AIDS 1987 |
PARD3B (rs11884476) |
3.4E-09 |
Significant, confirmed |
Caucasian, African |
[41] |
| blood donors, Sanquin Amsterdam |
2011 |
in vitro HIV-1 replication in macrophages |
DYRK1A (rs12483205) |
2.2E-05 |
Putative |
Caucasian |
[42] |
| ACS |
2011 |
progression to AIDS, or AIDS-related death |
AGR3 (rs152363) |
3.5E-06 |
Putative |
Caucasian |
[43] |
| Thailand |
2011 |
Nevaripine tolerance |
CCHCR1 (rs1265112) |
1.2E-08 |
Significant |
Asian |
[44] |
| African serodiscordant couples cohort | 2011 | HIV acquisition | African | [45] |
VL; viral load.